Gilead­'s newest ac­qui­si­tion: a liv­er dis­ease drug with $1B in peak sales po­ten­tial

Gilead’s ac­qui­si­tion of CymaBay Ther­a­peu­tics un­der­scores the com­pa­ny’s his­toric suc­cess in liv­er dis­eases and could bring in $1 bil­lion in peak an­nu­al sales.

Gilead an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER